Evolent has more than 1,400 clinicians—including 300 physicians—focused on improving health outcomes for cancer, cardiovascular disease, musculoskeletal conditions and more. Watch to learn how our evidence-driven, patient-first model helps produce more informed treatment decisions.
Other content in this Stream
Repairing Fragmented Care with Value-Based Strategies
Appearing on the Health Care Rounds podcast, Evolent Senior Director for Value Transformation Kamal Golla explains why value-based specialty care is primed for growth.
From every angle: Dr. Von Nguyen brings rare background to quest for high-value specialty care
Chief Clinical Officer Von Nguyen brings a background in value-based payment models, artificial intelligence and health plan operations to Evolent.
Why health plans need to refresh their surgical implant strategy
Barriers related to implantable devices often keep orthopedic procedures from being peformed outside the hospital.
AI-curated clinical pathways? Not so fast.
Could generative AI replace expert consensus for devising clinical guidelines? Our chief medical officer takes a look.
Value-based strategies for connecting primary and specialty care
To reduce the fragmentation of care for complex conditions, we need to take on the fee-for-service models that contribute to it, says Evolent’s Dr. Vishnukamal Golla.
Another Toxicity of Cancer Treatment
Cancer treatment and the time spent traveling for care are often very time-consuming. By recognizing and working to decrease time toxicity for patients with cancer, we can lessen their burden.
Dr. Sadie Dobrozsi Discusses the Future of Genetic Testing in Oncology and the Impact on Women’s Health
A stronger, unified voice in our scientific community will impact the accessibility of genetic testing so that it becomes standard preventive care for everyone who qualifies — and who wants it.
Evolent to acquire AI utilization management products and team from Machinify
Addition will help Evolent to increase first-pass approvals and streamline data collection in complex medical decision making.
Evolent and Careology form strategic care navigation partnership
Joint offering will seek to to enable more coordinated, connected and empowered journeys for people living with cancer in the U.S.
True peer-to-peer conversations will improve prior authorization
Dr. Matthew Walker writes in STAT about one big step to make peer conversations more collegial and productive.
10:51The “dystopian” state of primary care
Evolent's Dr. Kamal Golla speaks with the Healthcare Finance Management Association’s Voices podcast about the challenges of connecting primary and specialty care.
Evolent Announces Focus on Specialty Care With Rebrand, Unification of Solutions
Company's solutions are coming together to improve outcomes for people living with complex health conditions.
It's Cancer Prevention Month. Here are 11 ways to reduce your risk.
Our CMO, Dr. Andrew Hertler, talks to Yahoo Life about identifying which patients need genetic testing or aggressive cancer screening, the issues surrounding prophylactic surgery, and more.
Trends clinical leaders, hospital execs say will shape healthcare beyond 2024
Becker's highlights our CMO's predictions on the future of health care.
Prophylactic Mastectomy for Patients With High-Risk Gene Mutations
Dr. Andrew Hertler discussed the importance of prophylactic mastectomy for individuals carrying BRCA1, BRCA2 and other deleterious mutations.
Medicare Drug Price Negotiations and Anticipated Ripple Effects
Our vice president of pharmacy explores the hard-to-predict impacts of drug price negotiations on consumers, plans and pharmaceutical companies.
Pancreatic Cancer Screening, the New Guidelines, and Barriers to Care
Our CMO speaks with Urban Health Today about who should get screened, the role of primary care physicians in identifying at-risk individuals, and more.
Genetic Testing in Cancer Care: Considerations for a Condition-Based Approach
Two Evolent experts discuss the benefits of genetic testing in oncology in American Journal of Managed Care.
Evolent facilitates response to cancer drug shortages
Evolent takes a multifaceted approach to help providers navigate shortages of cisplatin, carboplatin and other anti-cancer drugs.
The Make-or-Break Moment for Payers in Specialty Care
Our chief strategy officer speaks with Becker's about the largely untapped potential of value-based specialty care.